United Therapeutics Corp (UTH.BE)
| Previous close | 219.20 |
| Open | 222.40 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 219.10 - 222.40 |
| 52-week range | 190.00 - 237.40 |
| Volume | |
| Avg. volume | 0 |
| Market cap | N/A |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | 01 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
Business WireCORRECTING and REPLACING PHOTO United Therapeutics Announces World’s First Successful Xenothymokidney Transplant
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C., April 26, 2024--Please replace the photo for release dated April 24, 2024 with the accompanying corrected photo.
- Business Wire
United Therapeutics Corporation to Report First Quarter 2024 Financial Results Before the Market Opens on Wednesday, May 1, 2024
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C., April 24, 2024--United Therapeutics Corporation (Nasdaq: UTHR), announced today that it will report its first quarter 2024 financial results before the market opens on Wednesday, May 1, 2024. A press release detailing the quarterly results will be issued that day at approximately 6:30 a.m. Eastern Time.
- Business Wire
United Therapeutics to Feature Clinical Data Across its Commercial and Development Portfolio at the American Thoracic Society 2024 International Conference
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C., April 16, 2024--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that recent research across its commercial and development portfolio will be presented at the American Thoracic Society (ATS) International Conference in San Diego on May 17-22, 2024. At ATS, United Therapeutics will host an educational industry theater on implementing treprostinil induction strategies in pulmonary hypertension, and the
